US Pharma MarketingMerck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout research Congress NIH Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout EU and US advisers split over AstraZeneca breast cancer drug Merck-Kelun ADC outperforms Keytruda…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Merck’s bet on an antibody-drug conjugate developed in China has paid off in a major Phase 3 lung cancer study, where sacituzumab tirumotecan paired with Keytruda sharply outperformed Keytruda alone in a subset of lung cancer patients.
Also, the NIH is down another leader, and Sam Altman-backed longevity startup Retro Biosciences raises more funds.
Source: STAT News Pharma